Evidence map›Paper›PMID 37073321›Full record

ReviewBiospektrum : Zeitschrift der Gesellschaft fur Biologishe Chemie (GBCH) und der Vereinigung fur Allgemeine und Angewandte Mikrobiologie (VAAM)2023

Teresa R Wagner, Sandra Burgstaller, Desiree I Frecot, Robert Lukowski, Ulrich Rothbauer

Open access · hybridAbstract readEnglish AbstractReview
In one paragraph

Review in Biospektrum : Zeitschrift der Gesellschaft fur Biologishe Chemie (GBCH) und der Vereinigung fur Allgemeine und Angewandte Mikrobiologie (VAAM), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Teresa R WagnerPharmazeutische Biotechnologie, Universität Tübingen, Tübingen, Deutschland.
Sandra BurgstallerPharmazeutische Biotechnologie, Universität Tübingen, Tübingen, Deutschland.
Desiree I FrecotPharmazeutische Biotechnologie, Universität Tübingen, Tübingen, Deutschland.
Robert LukowskiPharmakologie, Toxikologie und Klinische Pharmazie, Universität Tübingen, Tübingen, Deutschland.
Ulrich RothbauerPharmazeutische Biotechnologie, Universität Tübingen, Tübingen, Deutschland.
University of Tübingen · DENatural and Medical Sciences Institute · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

2023 marks the 30th anniversary of the discovery of single-domain antibody fragments in camelids, better known as nanobodies. This was the starting point for their tremendous success story in biomedicine. Here we highlight recent advances in the development of nanobodies for the detection of neutralizing SARS-CoV-2 antibodies, as biosensors for monitoring extracellular metabolites and as tracer molecules for non-invasive imaging of immune cells.

Identifiers

PMID37073321
PMCPMC10101533
OpenAlexW4365459146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.